There are currently 51 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.
Psychophysical Studies of Cancer Therapy Pain
NCT00515060
Recruiting
The Aim of this Study is to examine the feasibility of using quantitative sensory testing procedures, widely applied to the experimental study of sensory processing in humans both with and without various pain syndromes, to now characterize the psychophysical properties of neuropathic pain that has developed as a consequence of cancer therapy. Skin punch biopsies will be performed in patients with chemotherapy-induced pain to determine whether the impairment of nerve function is due to actual re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer, Pain
Register for Updates
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +13 locations
Conditions: Advanced Cancer
Register for Updates
Evaluating Disparities in Precision Oncology
NCT06081517
Recruiting
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2024
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Cancer, Advanced Cancer
Register for Updates
A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
Recruiting
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Florida Cancer Specialists, Lake Mary, Florida +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Register for Updates
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
NCT04419532
Recruiting
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +5 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
Register for Updates
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: City of Hope National Medical Center, Duarte, California +2 locations
Conditions: Advanced Cancer, Solid Tumor, Metastatic Cancer
Register for Updates
Psilocybin in Cancer Pain Study
NCT06001749
Recruiting
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Register for Updates
Care Planning Framework in Advanced Cancer (ABC123)
NCT05408507
Recruiting
Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients \>60 years old with recently diagnosed advanced, incurable cancer in for a first consultation at a participating medical oncology clinic. The team will pilot test the ABC123 framework delivery by an advanced practice provider working with a medical oncologist to inform the overall care planning process. This framework will routinely inc... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
09/19/2024
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Advanced Cancer
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mayo Clinic, Phoenix, Arizona +8 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT05076760
Recruiting
This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Register for Updates
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954
Recruiting
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Differentiated Thyroid Cancer, Advanced Cancer
Register for Updates